These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 573066)

  • 21. Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia.
    Laszlo J
    Semin Hematol; 1975 Oct; 12(4):409-32. PubMed ID: 1105793
    [No Abstract]   [Full Text] [Related]  

  • 22. Spontaneous megakaryocytic colony formation does not discriminate between essential thrombocythemia and polycythemia vera.
    Escoffre-Barbe M; Amiot L; Beaucournu P; Jego P; Grulois I; Grosbois B; Bernard M; Fest T; Lamy T; Fardel O
    Am J Hematol; 2006 Jul; 81(7):554-6. PubMed ID: 16755572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
    Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
    Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diagnostic and pathogenetic significance of some cytogenetic and cythochemical findings (leukocyte alkaline phosphatase) in systemic hemopathies with myeloproliferative tendencies].
    Cacciola E; Giustolisi R
    Haematologica; 1970; 55(5):311-32. PubMed ID: 4995787
    [No Abstract]   [Full Text] [Related]  

  • 25. Management of the myeloproliferative disorders : distinguishing data from dogma.
    Green AR; Vassiliou GS; Curtin N; Campbell PJ
    Hematol J; 2004; 5 Suppl 3():S126-32. PubMed ID: 15190294
    [No Abstract]   [Full Text] [Related]  

  • 26. Diagnostic and prognostic value of chromosome studies in cancer.
    Nowell PC
    Ann Clin Lab Sci; 1974; 4(4):234-40. PubMed ID: 4533399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [What vascular events suggest a myeloproliferative disorder?].
    Hachulla E; Rose C; Trillot N; Caulier-Leleu MT; Pasturel-Michon U
    J Mal Vasc; 2000 Dec; 25(5):382-387. PubMed ID: 11148402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New recommendations on chronic myeloproliferative diseases. New knowledge must yield new practice].
    Merup M; Löfvenberg E; Palmblad J
    Lakartidningen; 2009 Jan 14-20; 106(3):98-9. PubMed ID: 19248458
    [No Abstract]   [Full Text] [Related]  

  • 29. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia.
    Murphy S
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):9-13. PubMed ID: 9930551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Primary and secondary thrombocythemia: apropos of 39 cases].
    Bernadou A; Loo H; Prost RJ; Doumenc J; Zittoun R; Bilski-Pasquier G
    Sem Hop; 1968 Jun; 44(31):2092-100. PubMed ID: 4300454
    [No Abstract]   [Full Text] [Related]  

  • 31. [An improved method for biochemical measurement of the activity of neutrophil alkaline phosphatase and its application to myeloproliferative disorders].
    Tokuda M; Kawanishi K; Irino S
    Rinsho Ketsueki; 1991 Aug; 32(8):838-43. PubMed ID: 1942523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Essential thrombocythemia--a comparative study on polycythemia vera].
    Ohsaka A; Tsuboyama A; Kano Y; Furukawa Y; Takeda K; Akashi S; Komatsu N; Muroi K; Ohta M; Takagi S
    Rinsho Ketsueki; 1986 Mar; 27(3):285-91. PubMed ID: 3735683
    [No Abstract]   [Full Text] [Related]  

  • 33. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
    Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
    Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chromosome abnormalities in the myeloproliferative disorders.
    Dewald GW; Wright PI
    Semin Oncol; 1995 Aug; 22(4):341-54. PubMed ID: 7638632
    [No Abstract]   [Full Text] [Related]  

  • 36. EANM procedure guidelines for 32P therapy.
    EANM
    Eur J Nucl Med Mol Imaging; 2003 Mar; 30(3):BP17-9. PubMed ID: 12723560
    [No Abstract]   [Full Text] [Related]  

  • 37. [Clinico-hematological characteristics of acute transformation of chronic myeloproliferative syndromes].
    Hernández JM; San Miguel JF; González M; Moraleda JM; Moro MJ; Hernández J; Cuesta B; López Borrasca A
    Med Clin (Barc); 1991 Sep; 97(10):369-72. PubMed ID: 1745085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progenitor cell trafficking in physiologic conditions and in myeloproliferative diseases: quantification of CD34+ cells by polymerase chain reaction.
    Oppliger Leibundgut E; Brunold C; Marti D; Horn MP; Seiler C; Schroeder V; Schmid JP; Tobler A; Zwicky C
    Haematologica; 2005 Jul; 90(7):875-80. PubMed ID: 15996924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders.
    Bacher U; Haferlach T; Schoch C
    Cancer Genet Cytogenet; 2005 Jul; 160(2):179-83. PubMed ID: 15993276
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J; Fijnheer R; Walsh IB; Hermans MH
    Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.